A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer

摘要

IntroductionTraditional clonogenic survival and high throughput colorimetric assays are inadequate as drug screens to identify novel radiation sensitizers. We developed a method which we call the High Content Clonogenic Survival Assay (HCSA) that will allow screening of drug libraries to identify candidate radiation sensitizers.